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Transfer of T lymphocytes genetically modified with
T-cell receptors (TCR) specific for tumour-associated
antigens is a novel therapeutic approach for diverse
malignant diseases. However, efficacy as well as safety of
this therapy still needs to be improved. In order to
understand T cell trafficking and functionality in vivo, the
development of non-invasive and sensitive cell-tracking
technologies would be of high value. Moreover, clinical
translation of such technologies would further provide
possibilities to improve this therapeutic approach in
humans. We aim to establish a non-invasive, clinically
translatable imaging approach for in vivo monitoring of
adoptively transferred T cells engineered with selected
TCRs. We have previously isolated several TCRs specifi-
cally recognising peptides derived from diverse tumor
associated antigens and selected one TCR recognising
lymphoma cells with defined HLA-DR restriction.
Peripheral blood mononuclear cells from healthy donors
were retrovirally transduced with the selected TCR. To track
transduced T cells, we used an anti-murine TCRbmonoclo-
nal antibody (TCRmu), which binds to the murinzed region
of the introduced TCR. This antibody was either radioiodi-
nated with Iodine-124 or conjugated with a bifunctional
chelator and labelled with Zirconium-89. Labelled antibodies
were tested for stability and specific binding in vitro. A
xenogenic mouse model was established using Nod/SCID
mice injected intraperitoneally with lymphoma cells. After
tumour inoculation, we transferred TCR-transduced human
T cells and PET imaging was performed at different time
points post injection of 124I-TCRmu or 89Zr-TCRmu. Speci-
fic in vivo binding was evaluated by co-injection of an excess
of unlabelled antibody or isotype control antibody. In vivo
uptake was confirmed by autoradiography and immunos-
taining for human CD3 on tumour frozen sections.
We established labelling of TCR transduced T cells
using a specific antibody (TCRmu) marked with Iodine-
124 or Zirconium-89. After the radio-labelling, affinity and
specificity of the antibody was maintained while viability
and functionality of T-cells remained unaffected. In vivo
imaging of TCR-transduced T cells in the xenograft tumor
model revealed strong uptake on the tumour area.
Improved signal detection and reduced background was
observed using 89Zr-anti-TCRmu. These results corre-
spond to autoradiographic signals and detection of human
T cells on the tumour border. Injection of an excess of
unlabelled TCRmu showed depletion of human T cells in
vivo, enabling a possible approach to control potentially
autoreactive T cells in vivo.
In summary, we developed a non-invasive imaging
model for tracking specifically human TCR-engineered
lymphocytes in vivo. This model will be useful to monitor
adoptive transfer of TCR transgenic T cells in vivo and
therefore giving important information for further optimi-
sations regarding efficacy and safety of immunotherapeutic
approaches.
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